Update information

April 2026: Recommendations in section 1.1 on the detection of ovarian cancer in primary care have been removed from this guideline because they have been updated in section 1.5 of the NICE guideline on suspected cancer (April 2026).

We also simplified the guideline by removing recommendations on general principles of care that are covered in other NICE guidelines. This is a presentational change only, and no changes to practice are intended.

Minor changes since publication

January 2026: We removed the link to NICE's technology appraisal guidance on entrectinib for treating NTRK fusion-positive solid tumours from the section on systemic anticancer therapy for recurrent or relapsed ovarian cancer because the guidance has been withdrawn.

August 2025: We added links to relevant technology appraisal guidance on NTRK inhibitors in the section on systemic anticancer therapy for recurrent or relapsed ovarian cancer.

April 2025: We added links to relevant technology appraisal guidance in the section on managing advanced (stage 2 to 4) ovarian cancer and a new section on systemic anticancer therapy for recurrent or relapsed ovarian cancer.

January 2025: We added a link to NICE's HealthTech guidance on cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis (HTG569) to the section on intraperitoneal chemotherapy.

December 2017: Two out of date recommendations for research have been removed.

ISBN: 978-1-4731-9427-4